2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2267

Genome-Wide Pathway Analysis of Genome-Wide Association Studies On Systemic Lupus Erythematosus
Abstract Number: 980

Genomewide Association Study in Systemic Lupus Erythematosus: Known Loci
Abstract Number: 1874

Genomic Categories of Fatigue in Women with Fibromyalgia
Abstract Number: 2384

Giant Cell Arteritis and Cardiovascular Events in the French Apogee Cohort. A Population-Based Study Using the French Health Insurance System Database
Abstract Number: 2548

Global Molecular Effects of Tocilizumab Therapy in Synovial Biopsies of Early Rheumatoid Arthritis Patients
Abstract Number: 816

Glomerular Filtration Rate, Chronic Kidney Disease and Incidence of Physician Diagnosed Gout
Abstract Number: 1241

Glucocorticoid use Is associated with increase in HDL in Rheumatoid Arthritis Patients
Abstract Number: 321

Glycosylation of Vitamin D Binding Protein Reduced in Juvenile Idiopathic Arthritis Patients At Risk of Disease Extension
Abstract Number: 1366

Golimumab Administered Subcutaneously Every 4 Weeks in Chinese Patients with Active Ankylosing Spondylitis: Week 24 Safety and Efficacy Results From a Randomized, Placebo – Controlled Study
Abstract Number: 497

Golimumab Drug Utilization Patterns in Canada – Higher Retention Rate in Golimumab Treated Rheumatoid Arthritis Patients Compared to Etanercept and Adalimumab
Abstract Number: 1167

Golimumab in 25 Young Adults Affected by Juvenile Idiopathic ARTHRITIS NON Responders to OTHER Biological Agents: Preliminary DATA
Abstract Number: 1324

Golimumab, A Human Anti-TNF Monoclonal Antibody, Administered Subcutaneously Every Four Weeks As Monotherapy in Patients with Active Rheumatoid Arthritis Despite Disease Modifying Antirheumatic Drug Therapy: Week 104 Results of Clinical, Radiographic and Safety Assessments
Abstract Number: 1206

Gp96 Exacerbate the Inflammation of Rheumatoid Arthritis
Abstract Number: 822

Greater Than Expected Increased Mortality Following Fragility Fractures in Women and Men with Rheumatoid Arthritis
Abstract Number: 2073

Green Tea Epigallocatechin-3-Gallate Ameliorates Murine Arthritis by Inducing IDO Producing Dendritic Cells Via Nrf2 Antioxidant Pathway

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].